Advertisement

Triple therapy AMD trial to continue

Published on: 

The Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) is to continue as planned, following promising interim results and the positive recommendations of the independent Data and Safety Monitoring Committee.

Advertisement
Advertisement